President Donald Trump’s proposed 200% tariff on pharmaceutical imports has raised concerns in Australia about the potential impact on the Pharmaceutical Benefits Scheme (PBS) – a system that subsidises essential medicines to keep them affordable for Australians.
* * * * *
Understanding the PBS and the Tariff Threat
The PBS is a cornerstone of Australia’s healthcare system. It allows the government to negotiate lower prices with pharmaceutical companies, ensuring Australians pay a capped co-payment (e.g., $31.60 for most scripts), while the government covers the remainder.
This model has long been a source of frustration for U.S. pharmaceutical companies, which argue it undervalues their innovations and limits profits. These companies have lobbied the Trump administration to impose tariffs on Australian pharmaceutical exports, claiming the PBS creates unfair pricing practices.
Trump’s proposed 200% tariff on pharmaceutical imports is designed to incentivise drug manufacturing in the U.S. by penalising imports, with a 12–18 month grace period. Australia currently exports around $US1.6 billion ($2.5 billion AUD) in medicines and healthcare products to the U.S. annually – about 40% of its total pharmaceutical exports.
While the PBS itself doesn’t directly involve exports, these tariffs could have knock-on effects. Here’s how:
- Reduced demand for Australian drugs: Tariffs could make Australian pharmaceuticals more expensive in the U.S., reducing competitiveness and potentially pressuring companies like CSL to shift production offshore – disrupting Australia’s domestic industry.
- Leverage against PBS price controls: U.S. pharmaceutical lobby groups such as PhRMA have long criticised the PBS for aggressive price negotiations and delays in approving new drugs. Tariffs may be used as leverage to pressure Australia into relaxing these controls.
- Trade deal bargaining chips: There’s a risk that future trade negotiations could involve “implicit” pressure on Australia to pay higher prices for U.S. drugs in exchange for tariff exemptions – potentially straining the PBS’s $17.7 billion annual budget.
- Global pricing flow-on effects: If U.S. drug companies raise global prices to offset losses from Trump’s domestic pricing reforms (such as the “most favoured nation” rule), Australia could face higher drug costs or even reduced access to new treatments.
Still, the direct threat to the PBS is less clear-cut. The scheme primarily funds subsidies for medicines provided to Australian consumers – not exports. A blow to pharmaceutical exports may affect the broader economy or local companies, but it doesn’t dismantle the PBS itself.
Some mainstream media coverage has suggested the PBS could be “destroyed.” This is alarmist. While there are valid concerns about increased costs or delayed access, the scheme’s core mechanism – government negotiation for subsidised pricing – remains robust.
Social media posts on X also reflect public anxiety, with some claiming Australia could soon be paying U.S.-style prices for medicines. These fears are understandable, but for now, they are speculative and not supported by concrete policy changes.
Crucially, the PBS enjoys strong bipartisan political support. Before the last federal election, Labor vowed to protect it – perhaps anticipating future pressure from a Trump administration. That promise remains in place under the Albanese government.
Monash University experts have noted that tariffs would only directly affect the PBS if they became part of a broader political or trade deal – something that currently seems unlikely, given Australia’s cautious and measured trade policy stance.
There’s also helpful precedent: during negotiations for the Australia–U.S. Free Trade Agreement, the PBS was explicitly protected from U.S. interference, thanks in part to strong advocacy from then-Opposition Leader Mark Latham (before he went rogue).
Nonetheless, uncertainty remains. Trump’s tariff proposals are still being finalised, and Australian officials have described the U.S. stance as “very uncertain.” The situation is fluid and may change quickly.
One possible silver lining is Australia’s significant trade deficit with the U.S., which might lower its visibility as a tariff target. Or perhaps Trump will change his mind. Or forget about it altogether.
In summary, while the 200% tariff proposal could increase costs or delay access to some medicines, claims that it will “destroy” the PBS are exaggerated. The greater risk lies in economic pressure and trade negotiations – challenges that demand careful management, not panic.
For now, the PBS remains structurally sound, and the Albanese government appears firmly committed to defending it.
Also by Michael Taylor:
The Epstein Files: A Web of Hypocrisy, Denials, and a Fractured MAGA Movement
Dear reader, we need your support
Independent sites such as The AIMN provide a platform for public interest journalists. From its humble beginning in January 2013, The AIMN has grown into one of the most trusted and popular independent media organisations.
One of the reasons we have succeeded has been due to the support we receive from our readers through their financial contributions.
With increasing costs to maintain The AIMN, we need this continued support.
Your donation – large or small – to help with the running costs of this site will be greatly appreciated.
You can donate through PayPal or credit card via the button below, or donate via bank transfer: BSB: 062500; A/c no: 10495969
The orange gibbon with the bad hat is way out of control.I have a feeling that he’s soon going to bust.
Big Pharma and all the other greed corporations who are attempting to cash in on his lunacy can go fuck themselves.
Trump has pulled the plug on Australia – its time Australia pulled the plug on USA. The former days of gratitude for the outcome of the Battle of the Coral Sea are long over. It is time for Australia to stand on our own two feet and address our future which lies within Asia – not USA, UK or Europe. BRICS has more to offer for Australia than ANZUS, AUKUS or the 5 Eyes.
We should be out there negotiating new deals in the pharmaceutical sphere with other countries. We were dragged kicking and screaming into looking at sovereignty of our medical supplies due to COVID. Lets go a step further. Lets deal with the EU drug companies and medical products manufacturers for medical and surgical equipment, as well as prosthetics. These are some of the most expensive parts of the costs of medical treatment in Australia. Even if we cannot lower the cost, partnerships with these companies will bring more advanced manufacturing on-shore and protect our supply lines. If nothing else, we will protect CSL from some predicted losses by doing so.
If we do this we can expect higher value exports and an improvement in our balance of trade.
To ignore this is to allow the USA to dictate what and how we manage our own healthcare. That 200% tariff alone will damage Australian companies, no matter what, if we do not become pro-active.
I agree, now is the time for our politicians of all persuasions to stand firm and block Trump’s tariff gangsterism.
Hm, what would the LNP do if they were ruini…running the country?
On with the knee pads and kneel before the Orange Emperor with spread cheeks?
Guess we’ll won’t know the answers for years to come.
Let’s just hope that Labor doesn’t buckle under the pressure from the disturbed and demented git in the US.
Somehow, by any means, with as yet unknown leadership and policies, the world would be better off fighting for freedom from Trump and the festering USA, than just losing. If Trump’s filthy ignorant rotten instincts want change, let us all give him our change. Our changes may be positive and less unfair.